The local medical landscape is abuzz with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in clinical trials for treating obesity. This medication https://socialtechnet.com/story7364778/the-new-retatrutide-australia-a-potential-solution-for-weight-loss